BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34036385)

  • 1. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.
    Zhao T; Zhou Y; Wang Q; Yi X; Ge S; He H; Xue S; Du B; Ge J; Dong J; Qu L; Wang L; Zhou W
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34036385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
    Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
    Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
    [No Abstract]   [Full Text] [Related]  

  • 3. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
    Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
    Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
    [No Abstract]   [Full Text] [Related]  

  • 5. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
    Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
    Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway.
    Shou Y; Yue C; Wang Q; Liu J; Xu J; Miao Q; Liu D; Yang H; Liu Y; Zhang X
    Cell Death Dis; 2023 Mar; 14(3):232. PubMed ID: 37002206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
    Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
    Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
    Pan Y; Lu X; Shu G; Cen J; Lu J; Zhou M; Huang K; Dong J; Li J; Lin H; Song H; Xu Q; Han H; Chen Z; Chen W; Luo J; Wei J; Zhang J
    Cancer Res; 2023 Jan; 83(1):103-116. PubMed ID: 36264173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
    Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
    Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.
    Wang Q; Gao S; Shou Y; Jia Y; Wei Z; Liu Y; Shi J; Miao D; Miao Q; Zhao C; Liu C; Yang H; Xu T; Zhang X
    Int J Biol Sci; 2023; 19(4):1266-1283. PubMed ID: 36923928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
    Jin J; Xie Y; Zhang JS; Wang JQ; Dai SJ; He WF; Li SY; Ashby CR; Chen ZS; He Q
    Drug Resist Updat; 2023 Mar; 67():100929. PubMed ID: 36739809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
    Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
    J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.